Project Grant HT94252510085
Award Date
2/1/25
Completion Date
1/31/27
Dollars Obligated
$358K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ithaca, NY, USA
Similar Awards
This federal Project Grant award for $808,141.00, funded by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, is supporting research at Weill Medical College of Cornell University focused on "Targeting Inflammatory Pathways in Breast Cancer Brain Metastases for the Treatment of Edema and Radiation Necrosis Using Anti-VEGF Ultrasmall Particle Therapy." The award, with a performance period from February 1, 2025 to...
The federal Project Grant award in the amount of $847,501.00 was provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. Specifically, the award is funding research at Weill Medical College of Cornell University to investigate the role of BCL-XL in breast cancer metastasis...
The federal Project Grant award, totaling $1,419,023.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support the development of an early detection blood test for universal breast cancer screening to improve early diagnosis for women of all social and ethnic backgrounds. The award was granted to the Weill Medical College of Cornell University, a prominent academic medical institution, to...
The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This federal Project Grant award, with a total funding amount of $312,610.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research at the Weill Medical College of Cornell University focused on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER." This award, with a performance period from September 30, 2024 to September 29, 2026, will enable the Weill Medical...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,710,727.00 in funding to Health Research, Inc. (a non-profit organization) to conduct research on targeting the BRSK2 gene in aggressive breast cancer brain metastasis. The award period runs from Sep 30, 2024 to Sep 29, 2027. As a prime grantee, Health Research, Inc. will leverage its expertise in cancer biology, immunotherapy development, and biomarker...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...